Employers are struggling to find top talent. Candidates are struggling to stand out. ChatGPT can help you write job ...

A closely-watched lawsuit in the US Supreme Court has reached its conclusion, and sets an important precedent in the battle between brand owners and generic drugmakers over 'skinny' labels for ...

The US Supreme Court ruled yesterday, June 4, that pharmaceutical company Hikma’s generic cardiovascular drug does not infringe global biopharmaceutical company Amarin’s patents covering its drug ...

Earlier this year, Canada became the first major market in the world where generic forms of semaglutide became legal. The competition was on: Manufacturers raced to secure Health Canada approval so ...

Each day, millions of people pick up a prescription drug from their local pharmacy or mailbox. Most are affordable, with co-pays on average less than $7 for 90% of drugs. But for a growing number of ...

A unanimous Supreme Court reversed the Federal Circuit and held that Amarin did not plausibly allege that Hikma’s skinny label and marketing actively induced infringement of Vascepa’s ...

Drugmaker Hikma’s generic version of Irish-American company Amarin Pharma’s cardiovascular medication Vascepa did not infringe ‌Amarin’s patents, the US supreme court ruled on Thursday in a decision ...

US Supreme Court Backs Generic Drugmaker in 'Skinny Label' Patent Case By Blake Brittain WASHINGTON, June 4 (Reuters) - Drugmaker Hikma's generic version of Amarin Pharma's cardiovascular medication ...

With a resounding unanimous vote, the U.S. Supreme Court has sided with Hikma Pharmaceuticals, ruling that its generic version of Amarin’s fish oil-derived cardiovascular drug Vascepa does not ...